– UK, Chippenham – Vectura Group plc (LON: VEC), an industry-leading specialist inhalation CDMO, today announced the appointments of Jeanne Hecht and Jeanne Thoma to its Board as Independent Non-Executive Directors, effective from 31st December 2020.
“I’m delighted to welcome Jeanne Hecht and Jeanne Thoma to the Board of Vectura. Jeanne Hecht brings significant experience in drug development services globally, which directly supports our new strategic direction as a leading inhalation CDMO. Jeanne Thoma brings a unique blend of commercial, HR and business leadership experience in pharmaceutical services, which will bring new domain expertise to our Board supporting our new business model.” said Bruno Angelici, Chairman of Vectura.
About Jeanne Hecht
Jeanne Hecht was most recently CEO of Ora, Inc. a full-service pre-clinical and clinical ophthalmic drug and device development firm. Previously she served as Chief Operating Officer and was a Board Director of Median Technologies, a clinical services imaging business. Prior to this Jeanne had a substantial career with Quintiles, the world’s largest contract development services company, where she led global sales and strategic accounts.
Jeanne Hecht, said: “I am pleased to join the Board of Vectura at this exciting time and look forward to helping the Board build on the Company’s position as a leading development services business, helping the business deliver significant benefits to a growing number of customers and their patients.”
About Jeanne Thoma
Jeanne Thoma was most recently CEO and President of SPI Pharma, which provides specialist formulation and ingredient services to the pharmaceutical and nutritional industries, and is part of Associated British Foods plc. Previously she served as a senior advisor to the pharmaceutical industry and has had successful careers with Lonza where, in her last role, she was President and Executive Committee Member, and BASF where she served in senior key commercial roles in their pharmaceutical solutions business. Jeanne is a member of the Boards of Directors of ANI Pharmaceuticals Inc, an integrated specialty pharmaceutical company, and Avid Bioservices Inc, a contract development and manufacturing organisation focused on the development and cGMP manufacturing of biopharmaceutical mammalian cell culture products.
Jeanne Thoma, said: “As Vectura continues to build on its position as a leading inhalation specialist CDMO, I am excited to be working with the Board to help contribute to the Company’s future growth.”
About Vectura
Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For more information : https://www.vectura.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.